In this report, our goal is to check out health-related quality of life (HRQoL), depression and anxiety in patients with endocrine gastrointestinal (GI) tumors. HRQoL was researched and depression and anxiety with the Hospital Anxiety and Depression Scale. Furthermore, patient views of the significance of and satisfaction with chosen HRQoL factors were examined. Semi-structured interviews were carried out to find disease and treatment-related distress, what comprises a high quality of life and techniques to “keep a good mood” between these patients. Sufferers claimed a comparatively good health-related quality of life HRQoL and minimal degrees of depression and anxiety. Nevertheless, they reported a reduced HRQoL than could be predicted for healthy people of comparable age and sex. Staff members gave an even more depressed view of patient satisfaction with health-related quality of life HRQoL factors than did patients, and staff personnel failed to correctly assess individual patients’ degrees of depression and anxiety. Satisfaction discrepancies for health-related quality of life aspects could identify patients having a poor quality of life. HRQoL, depression and anxiety didn’t alter considerably throughout the initial year of therapy.
Video: Overview of Methods for Measuring Health-Related Quality of Life
Endocrine pancreatic tumors
Quality of life in cancer patients
Why measure health-related quality of life HRQoL and who should measure it?
HRQoL in patients with endocrine GI tumors
AIMS OF THE THESIS
Biochemical tumour markers
HRQoL, anxiety and depression
Importance of health-related quality of life HRQoL aspects
Satisfaction with HRQoL aspects
Psychosocial function in patients with endocrine GI tumours
Summaries of Studies I-V
Study I: Quality of life in patients with endocrine tumors of the
gastrointestinal tract: patient and staff perceptions.
Study II: Health-related quality of life in patients with endocrine tumour
of the gastrointestinal tract.
Study III: Importance-satisfaction discrepancies are associated with
health-related quality of life in five-year survivors of endocrine
Study IV: Quality of life, anxiety and depression in patients with carcinoid
tumours during the first year of treatment with α-interferon
and/or a somatostatin analogue.
Study V: Distress, quality of life and strategies to “keep a good mood”……
Download URL 2: Visit Now
Source: Uppsala University Library